Stonking Small Caps: shares soar on FDA approval
The enhanced medical imaging delivered by this company’s brilliant technology appears to have considerable potential in a huge market and it is yet another company where COVID-19 has accelerated interest. Long-awaited FDA approval for its drug-device combination product has seen the shares soar, it's now down to effective commercialisation.
A news release on 25 May 2021 concerning a study carried out in longer-term lung damage after COVID-19 determined that specialised scans had found abnormalities in the lungs of some COVID-19 patients more than three months - and in some cases, nine months - after leaving hospital, when other clinical measurements were normal. Principal Investigator Prof Fergus Gleeson, Professor of Radiology at the University of Oxford, said: "Many COVID-19 patients are still experiencing breathlessness several months after being discharged from hospital, despite their CT scans indicating that their lungs are functioning normally. Our follow-up scans using hyperpolarised xenon MRI have…